Payment overview · 2025
General Payments
$604.75
32 reported records · 8 companies
Healthcare provider profile · identity verified
Eboni Farmer, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · GREENSBORO, NC · NPI 1891447314
Verified facts
What the public records show
CMS Open Payments records show Eboni Farmer, FNP received $604.75 in general payments during 2025 across 32 reported records.
Lilly USA, LLC accounted for 41.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $250.41 | 41.4% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $204.61 | 33.8% | 14 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.67 | 7.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.93 | 6.1% | 2 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $19.23 | 3.2% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.77 | 3.1% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.80 | 2.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.33 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $604.75 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $250.41 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $132.09 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.54 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.37 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.67 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 494 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 355 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 291 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 81 |
| Losartan Potassium | Losartan Potassium | 212 | 65 |
| Gabapentin | Gabapentin | 194 | 54 |
| Furosemide | Furosemide | 183 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 53 |
| Lisinopril | Lisinopril | 150 | 52 |
| Metformin Hcl | Metformin Hcl | 139 | 40 |
| Prednisone | Prednisone | 134 | 95 |
| Oxycodone Hcl | Oxycodone Hcl | 128 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 125 | 29 |
| Omeprazole | Omeprazole | 125 | 50 |
| Potassium Chloride | Potassium Chloride | 120 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 107 | 27 |
| Simvastatin | Simvastatin | 105 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 32 |
| Glipizide Er | Glipizide | 93 | 25 |
| Trazodone Hcl | Trazodone Hcl | 92 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 82 | 26 |
| Lorazepam | Lorazepam | 82 | 14 |
| Tramadol Hcl | Tramadol Hcl | 79 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 16 |
| Ozempic | Semaglutide | 76 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 22 |
| Sertraline Hcl | Sertraline Hcl | 70 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 15 |
| Clonazepam | Clonazepam | 68 | 15 |
| Jardiance | Empagliflozin | 67 | 19 |
| Farxiga | Dapagliflozin Propanediol | 65 | 11 |
| Gemtesa | Vibegron | 65 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 18 |
| Metformin Hcl Er | Metformin Hcl | 60 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 11 |
| Bupropion Xl | Bupropion Hcl | 57 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 19 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Azithromycin | Azithromycin | 53 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 13 |
| Donepezil Hcl | Donepezil Hcl | 51 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 46 |
| Montelukast Sodium | Montelukast Sodium | 50 | 15 |
| Meloxicam | Meloxicam | 48 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 11 |
| Ezetimibe | Ezetimibe | 46 | 18 |
| Diazepam | Diazepam | 45 | suppressed |
| Allopurinol | Allopurinol | 43 | 15 |
| Eliquis | Apixaban | 43 | 13 |
| Nystatin | Nystatin | 43 | 19 |
| Alendronate Sodium | Alendronate Sodium | 42 | 12 |
| Ondansetron Odt | Ondansetron | 42 | 13 |
| Clonidine Hcl | Clonidine Hcl | 41 | 11 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Glipizide | Glipizide | 39 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Atenolol | Atenolol | 36 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 27 |
| Linzess | Linaclotide | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 21 |
| Celecoxib | Celecoxib | 27 | 12 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Ramipril | Ramipril | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Zoloft | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $604.75 · 32 records | Lilly USA, LLC | CONTRAVE, CREON, Dexcom G6 Transmitter, IMCIVREE, LINZESS, MONOFERRIC, MOUNJARO, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error